180 Life Sciences Corp Stock Price, News & Analysis

180 Life Sciences Corp. (NASDAQ: ATNF) announced the publication of a review titled ‘Treatments for early stage Dupuytren’s disease: an evidence-based approach’ in The Journal of Hand Surgery (European Volume). The review, authored by Professor Jagdeep Nanchahal, outlines limitations of current treatments for late-stage Dupuytren’s disease and highlights the efficacy of adalimumab in early-stage cases. A phase 2a and phase 2b trial showed positive results, with significant reductions in nodule hardness and size. CEO Dr. James Woody expressed optimism about advancing anti-TNF treatments for early-stage patients.

180 Life Sciences Corp. (NASDAQ: ATNF) announced its engagement of Kinexum to aid in the submission of a Marketing Authorisation Application (MAA) for adalimumab to treat progressive early-stage Dupuytren’s disease. The MAA will be submitted to the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), seeking a Conditional Marketing Authorisation (CMA). The company estimates spending approximately $900,000 to $1,000,000 over the next three quarters for this initiative. This move reflects the company’s ongoing commitment to address unmet medical needs through innovative clinical programs.

180 Life Sciences Corp. (NASDAQ: ATNF) announced on January 4, 2023, that it has regained compliance with Nasdaq's Minimum Bid Price Requirement. The company received a letter confirming that its common stock's closing bid price remained at or above $1.00 per share for 10 consecutive business days. This compliance is crucial for maintaining its listing on the Nasdaq Stock Market. 180 Life Sciences focuses on developing clinical programs aimed at addressing significant unmet medical needs, particularly through a novel treatment for inflammatory disorders.

180 Life Sciences Corp. (NASDAQ: ATNF) announced a review on Dupuytren’s disease published in Trends in Molecular Medicine, led by Professor Jagdeep Nanchahal from the University of Oxford. The review details the disease's biology, genetics, and key role of chronic inflammation. It identifies tumor necrosis factor (TNF) as a therapeutic target, with promising results from a phase 2b trial using anti-TNF treatment. CEO Dr. James Woody highlighted the unmet medical need for effective treatments for early-stage Dupuytren’s disease.

PALO ALTO, Calif., Dec. 29, 2022 – 180 Life Sciences updates shareholders on clinical programs targeting Dupuytren’s disease, frozen shoulder, and postoperative delirium. A phase 2B trial on Dupuytren's showed promising results, with plans for a UK marketing authorization application targeted for mid-2023. The company is enhancing recruitment strategies for the frozen shoulder trial, while preparations for the postoperative delirium trial are on track. Despite ongoing litigation, the company believes it is in a stronger cash position following recent financing and a completed reverse stock split.

180 Life Sciences Corp. (NASDAQ: ATNF) has completed a registered direct offering of 1,714,286 shares of common stock and accompanying warrants, raising approximately $6 million in gross proceeds. The offering was conducted with a healthcare-focused U.S. institutional investor at a purchase price of $3.50 per share. Proceeds from the offering will be allocated to research and development, including preparations for a marketing authorization application for Dupuytren’s contracture in the UK. The warrants are exercisable after six months and expire in five years.

180 Life Sciences Corp. (NASDAQ: ATNF) has announced a definitive agreement with a U.S. institutional investor to sell 1,714,286 shares and warrants to purchase up to 2,571,429 shares at a price of $3.50 per share. The offering is expected to close on or around December 22, 2022, with gross proceeds anticipated to be approximately $6 million. Funds from this offering will be directed towards research and development, a marketing authorization application, and general corporate purposes. A.G.P./Alliance Global Partners is acting as the sole placement agent.

180 Life Sciences Corp. (NASDAQ: ATNF) announced a one-for-20 reverse stock split effective December 19, 2022, to comply with NASDAQ's minimum bid requirement of $1.00. The total shares will decrease from approximately 40.5 million to about 2.0 million. The reverse split will not affect the par value or authorized shares. All outstanding options and warrants will be adjusted accordingly. This action was approved by shareholders during a special meeting on December 15, 2022. The company remains focused on addressing unmet medical needs through its clinical programs.

180 Life Sciences Corp. (NASDAQ: ATNF) met with the UK MHRA to discuss Dupuytren's disease treatment data on October 31, 2022. They provided information about nodule size and hardness as surrogate markers. The MHRA noted that reducing nodule size may not correlate with disease progression and requested supporting literature on adalimumab's clinical safety. CEO Dr. James Woody stated they plan to submit a marketing approval application in 2023, though approval is not guaranteed. The company addresses significant unmet medical needs in Dupuytren's disease, impacting approximately 4% of the Western population.